Vineet Laboratories Limited is an India-based company engaged in the business of drug intermediates and bulk drugs. The Company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates products include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. The Company also exports API intermediates, fine chemicals, and custom synthesis molecules.
Vineet Laboratories Financial Highlights
- Revenue: Vineet Laboratories reported revenue of ₹76.99 crore in FY25 vs ₹151.05 crore in FY24. It showed a decrease of 49.03% on a yearly basis.
- Operating Profit: Vineet Laboratories reported an operating loss of ₹20.78 crore in FY25 vs ₹0.36 crore in FY24. It showed a decrease of 5,872.22% on a year-on-year basis.
- Net Profit: Vineet Laboratories reported a net loss of ₹20.19 crore in FY25 vs ₹1.03 crore in FY24. It showed a decrease of 2,060.19% on a yearly basis.
Vineet Laboratories Quarterly Result Highlights
- Vineet Laboratories reported revenue of ₹15.70 crore in Dec 2025, compared with ₹17.43 crore in Sep 2025, representing a decrease of 9.93% on a quarter-on-quarter (QoQ) basis.
- Vineet Laboratories reported an operating profit of ₹0.82 crore in Dec 2025, compared with ₹0.37 crore in Sep 2025, representing an increase of 121.62% on a quarter-on-quarter (QoQ) basis.
- Vineet Laboratories reported a profit of ₹0.85 crore in Dec 2025, compared with ₹0.40 crore in Sep 2025, reflecting an increase of 112.50% on a QoQ basis.
- The earnings per share (EPS) of Vineet Laboratories stood at ₹21.90 during Dec 2025.
